Aeon's Migraine: Stock Plummets as Drug Test Fails - Orange County Business Journal
Aeon Biopharma Inc.’s stock plunged 53% in intraday trading May 3 on the company’s announcement of disappointing results from testing of its migraine drug. The Irvine-based clinical-stage company (NYSE: AEON) said its ABP-450 treatment for the prevention of chronic migraine did no better than placebo in a Phase 2 trial.